← Back to Clinical Trials
Recruiting NCT06596083

NCT06596083 The Effects of Ketone Ester Supplementation During a 5 Week Live High, Train Low Altitude Training Camp

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06596083
Status Recruiting
Phase
Sponsor KU Leuven
Condition Hypoxia
Study Type INTERVENTIONAL
Enrollment 18 participants
Start Date 2024-09-10
Primary Completion 2024-10-15

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 35 Years
Study Type INTERVENTIONAL
Interventions
Placebo supplementKetone ester supplement

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 18 participants in total. It began in 2024-09-10 with a primary completion date of 2024-10-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to investigate the effects of post-exercise and pre-sleep exogenous ketosis via oral ketone ester supplementation during a 5 week simulated altitude training camp.

Eligibility Criteria

Inclusion Criteria: * Physically fit and regularly involved in physical activity (2-5h per week) * Good health status confirmed by a medical screening * Non-smoking Exclusion Criteria: * Any kind of injury/pathology that is a contra-indication to perform high-intensity exercise * Any kind of injury/pathology that is a contra-indication for exposure to hypoxia * Ongoing pregnancy or breastfeeding * intake of any medication or nutritional supplement that is proven to affect exercise performance during the last month prior to the start of the study * Involvement in elite athletic training at a semi-professional or professional level * Exposure to altitudes higher than 1500 m during the 3 months prior to the start of the study * Blood ferritin levels below 30 ng/mL * Current participation in another research trial * Any other argument to believe that the subject is unlikely to succesfully complete the full study protocol

Contact & Investigator

Central Contact

Wout Lauriks

✉ wout.lauriks@kuleuven.be

📞 +32474360778

Principal Investigator

Chiel Poffé

PRINCIPAL INVESTIGATOR

KU Leuven

Frequently Asked Questions

Who can join the NCT06596083 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 35 Years, studying Hypoxia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06596083 currently recruiting?

Yes, NCT06596083 is actively recruiting participants. Contact the research team at wout.lauriks@kuleuven.be for enrollment information.

Where is the NCT06596083 trial being conducted?

This trial is being conducted at Leuven, Belgium.

Who is sponsoring the NCT06596083 clinical trial?

NCT06596083 is sponsored by KU Leuven. The principal investigator is Chiel Poffé at KU Leuven. The trial plans to enroll 18 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology